Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting No phase listed Observational

An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

ClinicalTrials.gov ID: NCT05712473

Public ClinicalTrials.gov record NCT05712473. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective Observational Multicenter Real-World Registry Assessing the Impact of the Use of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this observational research is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan. Participants will be enrolled at their physician's office at the time of referral for PYLARIFY PET and will be followed for up to 5 years. Data concerning their prostate cancer diagnostics and treatment will be collected at 6-month intervals.

Study identification

NCT ID
NCT05712473
Recruitment status
Active, not recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
Lantheus Medical Imaging
Industry
Enrollment
500 participants

Conditions and interventions

Interventions

Diagnostic Test

Eligibility (public fields only)

Age range
21 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 21, 2023
Primary completion
Jan 31, 2031
Completion
Apr 30, 2031
Last update posted
Sep 14, 2026

2023 – 2031

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
Urology Centers of Alabama Homewood Alabama 35209
Arkansas Urology Little Rock Arkansas 72211
Urology Associates of Central California Fresno California 93720
Comprehensive Urology Medical Group Los Angeles California 90048
Pasadena Urological Medical Group Pasadena California 91101
Comprehensive Urology Royal Oak Michigan 48076
Urology of St. Louis St Louis Missouri 63141
Adult & Pediatric Urology Omaha Nebraska 68114
Keystone Urology Specialists Lancaster Pennsylvania 17604
Urology Associates Nashville Nashville Tennessee 37209
Potomac Urology Alexandria Virginia 22311
Urology of Virginia Virginia Beach Virginia 23462

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05712473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 14, 2026 · Synced Sep 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05712473 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →